A mechanism-driven treatment for chronic lymphocytic leukemia?

New England Journal of Medicine

Volumn 369, Issue 1, 2013, Pages 85-87

  Foà, Robin ^a   Guarini, Anna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; IBRUTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID;

ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; BONE MARROW; CANCER IMMUNOTHERAPY; CELL SURVIVAL; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; EDITORIAL; FOLLOW UP; GENE SEQUENCE; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA CELL; LEUKEMIA REMISSION; LIFE EXPECTANCY; LYMPH NODE; LYMPHOCYTOSIS; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; SPLEEN;

EID: 84879749523     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1303054     Document Type: Editorial

References (8)

1. Contri A, Brunati AM, Trentin L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005;115:369-78. (Pubitemid 40385478)
2. Dühren-von Minden M, Übelhart R, Schneider D, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012;489:309-12.
3. Hoogeboom R, van Kessel KP, Hochstenbach F, et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med 2013;210:59-70.
4. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88-94.
5. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42.
6. Tavolaro S, Chiaretti S, Messina M, et al. Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors. Leuk Res 2010;34:733-41.
7. Guarini A, Chiaretti S, Tavolaro S, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood 2008;112:782-92.
8. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013;121:1403-12.